Posted December 7, 2020. Past health advisories and alerts are archived for historical purposes and are not maintained or updated.
We are sharing information from the WA Department of Health (DOH) about bamlanivimab, a monoclonal antibody treatment for COVID-19 that was recently granted an emergency use authorization by the FDA.
On Nov. 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients (>12 years old and >40 kg) who are at high risk for progressing to severe COVID-19 and/or hospitalization.
The Department of Health and Human Services purchased 300,000 doses of bamlanivimab from the manufacturer and began distributing weekly allocations to states during the week of Nov. 9, 2020. Doses were distributed to states and initially sent only to hospitals.
During the week of Nov. 23, 2020, any health care facility in Washington will be eligible to receive the medication from DOH. If the demand for medication from health care facilities in Washington exceeds the amount allocated to the state, DOH will allocate doses proportionally to facilities based on the population of the county. Doses will also be set aside for tribal clinics. Doses distributed through the government will be provided free of charge. Any health care facility able to abide by the requirements in the provider fact sheet will be eligible to receive the medication.
For complete details and how to request doses, please review this document.
